Sign inCreate account

Report workspace tools

NCT03867084COMPLETEDanonymous

A Phase 3 Double-blinded, Two-arm Study to Evaluate the Safety and Efficacy of Pembrolizumab (MK-3475) Versus Placebo as Adjuvant Therapy in Participants With Hepatocellular Carcinoma and Complete Radiological Response After Surgical Resection or Local Ablation (KEYNOTE-937)

Sponsor

Source record

Merck Sharp & Dohme LLC

Phase

Source record

Phase 3

Modality

AI-normalized

monoclonal antibody

Target

AI-normalized

Hepatocellular Carcinoma (HCC)

Indication / condition

AI-normalized

Hepatocellular Carcinoma

Intervention

Source record

Pembrolizumab, Placebo

Source & freshness

Source record

NCT ID

NCT03867084

Original source

ClinicalTrials.gov

Source last updated

Apr 24, 2026

Ingested at

May 31, 2026

Internal sync

Jun 05, 2026

Model version

trialsignal-ai-v1

Normalized confidence

88%

Validation status

validated

Open original registry record
View original source fields

NCT ID

NCT03867084

Title

A Phase 3 Double-blinded, Two-arm Study to Evaluate the Safety and Efficacy of Pembrolizumab (MK-3475) Versus Placebo as Adjuvant Therapy in Participants With Hepatocellular Carcinoma and Complete Radiological Response After Surgical Resection or Local Ablation (KEYNOTE-937)

Sponsor

Merck Sharp & Dohme LLC

Status

COMPLETED

Phase

Phase 3

Condition raw

Hepatocellular Carcinoma

Condition normalized

Hepatocellular Carcinoma

Modality raw

Hepatocellular Carcinoma

Modality normalized

monoclonal antibody

Target raw

Hepatocellular Carcinoma (HCC)

Target normalized

Hepatocellular Carcinoma (HCC)

Interventions

Pembrolizumab, Placebo

Public preview

Source record

This clinical trial evaluates the safety and efficacy of pembrolizumab (MK-3475) as adjuvant therapy in patients with HCC who have achieved complete radiological response following surgical resection or local ablation. The study aims to demonstrate superiority in recurrence-free survival (RFS) and overall survival (OS) compared to placebo.

AI-generated analysis supports research triage only. Verify source records, publications, sponsor disclosures and IP databases before making diligence decisions. Model: trialsignal-ai-v1.

Report access

Create an account to unlock this report

Choose the access model that matches the job: one urgent report, reusable credits for project work, or unlimited monthly access with AI and folders.

Full protocol, outcomes, eligibility, contacts and results sections
Patent/IP landscape with verified records when available
Board-ready PDF export with source provenance
Save to folders and synthesize multiple assets in premium workspace
Create account
Sign in

Create a free account first, then unlock a single report, buy credits or subscribe.

TrialSignal

Clinical trial intelligence report

A Phase 3 Double-blinded, Two-arm Study to Evaluate the Safety and Efficacy of Pembrolizumab (MK-3475) Versus Placebo as Adjuvant Therapy in Participants With Hepatocellular Carcinoma and Complete Radiological Response After Surgical Resection or Local Ablation (KEYNOTE-937)

Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.

Generated

Jun 13, 2026

NCT ID

NCT03867084

Status

COMPLETED

Phase

Phase 3

Sponsor

Merck Sharp & Dohme LLC

Executive brief

Investment-Ready Snapshot

This clinical trial evaluates the safety and efficacy of pembrolizumab (MK-3475) as adjuvant therapy in patients with HCC who have achieved complete radiological response following surgical resection or local ablation. The study aims to demonstrate superiority in recurrence-free survival (RFS) and overall survival (OS) compared to placebo.

Source & freshness

Provenance

SourceClinicalTrials.gov
Source updatedApr 24, 2026
Internal syncJun 05, 2026
Model versiontrialsignal-ai-v1

https://clinicaltrials.gov/study/NCT03867084

Indication

Hepatocellular Carcinoma

Modality

monoclonal antibody

Target

Hepatocellular Carcinoma (HCC)

Intervention

Pembrolizumab, Placebo

Source record

Protocol Description

Detailed source ingestion pending.

Source record

Outcome Measures

Detailed source ingestion pending.

Source record

Eligibility

Detailed source ingestion pending.

AI analysis

Known Results And Readout Context

Detailed source ingestion pending.

IP intelligence

Patent And IP Landscape

Detailed source ingestion pending.

Source record

Contacts

Detailed source ingestion pending.